Background <p>Checkpoint inhibitor-induced liver injury (ChILI) is an immune-related adverse reaction, occurring in patients with cancer receiving immune checkpoint inhibitors (CPI). ChILI is currently managed with high doses of corticosteroids which carry their own risks and potential side effects, and the lack of available biomarkers makes monitoring patients at risk of developing ChILI a challenge. There is no specific test…
Circulating exhausted CD8+ effector memory cells differentiate immune checkpoint inhibitor-induced liver injury from other acute immune-mediated liver injuries
Journal for ImmunoTherapy of Cancer | | Astbury, S., Atallah, E., Grove, J. I., Bozward, A. G., Davies, S. P., Sheehan, M. J., Kumpf, S. W., Qian, J., Krajewska, N. M., Wootton, G. E., Lingaya, M. R., Kresnik, D., Radulescu, F., Rao, A., Franks, H., Ruiz-Ortega, L., Riveiro-Barciela, M., Ramaiah, S. K., Lanz, T. A., Ji, C., Patel, P. M., Oo, Y. H., Aithal, G. P.
Topics: blood-cancer, immunotherapy, targeted-therapy, research
Read the full article at Journal for ImmunoTherapy of Cancer